Long-term results of a phase 2 study of neoadjuvant chemotherapy combined with tislelizumab followed by radiotherapy for bladder-preserving treatment in selected high-risk/locally advanced muscle invasive urothelial bladder cancer (HOPE-02).Feng Wen, Yali Shen, Tianhai Lin et al.|Journal of Clinical Oncology|2025Cited by 2